Global botulinum toxin industry to 2026

Dublin, October 6, 2021 (GLOBE NEWSWIRE) – The “Botulinum Toxin Market – Growth, Trends, Impact of COVID-19, and Forecast (2021 – 2026)” report was added to offer.

The botulinum toxin market was valued at USD 3,601.5 million in 2020 and is expected to reach USD 7,854.9 million by 2026, registering a CAGR of 9.94% during the forecast period.

Manufacturers of cosmetic and cosmetic fillers have had to shut down production and supply units due to the lockdown imposed at the start of the COVID-19 epidemic around the world. According to a Hamilton Fraser Cosmetic Insurance survey, conducted in March 2020, of 1,360 cosmetic practitioners in the UK to assess the impact of the pandemic on cosmetic procedures, said 99.78% of practitioners have revealed that their practice had been affected during the current period. pandemic. Additionally, consumers are also researching home cosmetic treatments online. Thus, cosmetics brands can take advantage of this opportunity to renovate their online offerings, offer online consultation services and invest in the right technologies, such as chatbots and augmented / virtual reality, as more and more consumers seek cosmetic advice from the comfort of their own home. during the pandemic, which reduces the risk of becoming infected. Thus, COVID-19 has strongly impacted the botulinum toxin market around the world. However, the situation is gradually improving.

The growth of the global botulinum toxin market is currently being driven by various factors. These include the growing demand for cosmetic procedures, increasing research and development initiatives to expand the therapeutic applications of botulinum toxin and the growing preference of patients for non-invasive or minimal treatments, associated with the development of new products. . For example, according to a 2019 report from the International Society of Aesthetic Plastic Surgery, 6,271,488 botulinum toxin procedures have been performed worldwide, which represents 46.1% of the total non-invasive procedures. The main non-surgical procedure performed in women in 2019 was botulinum toxin, which accounted for more than 5,429,754 procedures. Almost 841,735 men have undergone botulinum procedures.

The increasing quality of care, improved professional services and the availability of minimally invasive surgeries by highly qualified cosmetic surgeons have contributed to the growth in the volume of procedures. In addition, technological advancements, the introduction of cost-effective cosmetic products, an aging population, and the growing incidence of cosmetic issues, such as crow’s feet and lateral canthal lines, are also driving the market growth of the botulinum toxin worldwide. For example, in January 2019, in South Korea, Huons Co. Ltd launched the botulinum toxin product Liztox, which is specially designed to treat forehead wrinkles. In the current scenario, patients are demanding a wide range of products to treat more and more areas of the face, increasing the average time and money spent on each patient in clinics around the world. Therefore, due to the increasing demand and the urge to look attractive, these procedures are widely performed by celebrities and their fans, due to huge media coverage, which makes them more socially acceptable. However, the side effects of the available products, the lack of reimbursement policies supporting cosmetic procedures, and the high cost of the products may limit the rate of adoption of botulinum toxin during the forecast period.

Key market trends

The cosmetic applications segment holds a significant share

There is a growing demand for aesthetic appearance among individuals who have created a subsequent demand for botulinum toxin procedures all over the world. People’s worries about their appearance are gradually increasing, both in the developed and developing world; thus, there is an increase in the number of cosmetic surgeries performed, each year.

According to recent data from the American Society of Plastic Surgeons (ASPS), of the 2,630,832 non-invasive cosmetic procedures performed in the United States in 2019, botulinum toxin type A tops the list with 1,301,823 procedures. Botulinum toxin injection for the treatment of wrinkles is one of the most frequently performed cosmetic procedures in the world, and it is one of the most common entry procedures for clinicians looking to integrate treatments. aesthetic in their practice.

Globally, increasing demand for modern beauty standards has created a massive growth platform for botulinum toxin A products across the world. Additionally, the therapeutic applications of botulinum toxins have opened doors for growth across the healthcare platform.

According to the National Clinical Trials Registry (NCT), as of June 18, 2021, there were more than 312 ongoing and planned clinical trials related to botulinum toxin A through different phases of development for various indications. Additionally, in March 2021, Revance announced that the long-awaited and longer-lasting neuromodulatory drug candidate DaxibotulinumtoxinA for Injection (DAXI), a botulinum toxin type A formulated with a new peptide excipient or combined treatment of glabella, dynamic forehead and the lateral canthal lines are close to FDA approval. In December 2020, the company announced the results of its Phase 2 upper facial line study of DAXI. These factors are expected to have a positive impact on the market in the future.

North America dominates the market and is expected to do the same during the forecast period

North America is expected to dominate the world market. Medico-aesthetic technology has advanced rapidly over the past two decades in the region. Highly advanced technologies have offered a wide range of products and solutions to patients seeking medical assistance.

According to the American Society for Aesthetic Plastic Surgery, in 2019, 1,301,823 procedures were performed with botulinum toxin products (Botox, Dyport, Xeomin), which accounted for 45% of the total cosmetic procedures in the country.

There is also increased competition in the US botulinum toxin market which is expected to intensify with the launch of Jeuveau. Evolus Inc. received U.S. FDA approval in 2019 for its flagship product, Jeuveau, for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and / or procerus muscle activity in the body. ‘adult. Likewise, Daewoong Pharmaceutical, in 2019, also officially launched Nabota, its botulinum toxin (BTX) strain, in the United States.

Additionally, in April 2021, Aquavit Holdings LLC announced that it had acquired an exclusive license to register, market and market a botulinum toxin (DTX-021) in the United States and Canada. Hence, all of these approvals and launches have contributed to the growth of the overall market and is expected to continue the same trend during the forecast period.

Competitive landscape

The botulinum toxin market has evolved rapidly in recent years. The industry has observed significant changes in the adoption of market strategies such as product development, mergers and acquisitions in recent years. Thus, the botulinum toxin market has become a very competitive industry. The main companies in the market are Galderma, Evolus, Inc., Merz Pharma GmbH & Co. KGaA, AbbVie Inc. (Allergan), Ipsen Pharma, among others.

Additional benefits:

Main topics covered:




4.1 Market overview
4.2 Market drivers
4.2.1 Growing demand for cosmetic procedures
4.2.2 Increase research and development initiatives to extend the therapeutic applications of botulinum toxin
4.3 Market restrictions
4.3.1 Adverse reactions associated with botulinum toxin
4.3.2 Lack of reimbursement policies supporting cosmetic procedures
4.4 Porter’s five forces analysis

5.1 Application
5.2 End user
5.3 Geography

6.1 Company profiles
6.1.1 Merz Pharma GmbH & Co. KGaA
6.1.2 AbbVie Inc. (Allergan)
6.1.3 Galderme
6.1.4 Évolus, Inc.
6.1.5 Revance Therapeutics Inc.
6.1.6 HUGEL, Inc.
6.1.7 Ipsen Pharma
6.1.8 United States WorldMeds LLC


For more information on this report, visit

CONTACT: CONTACT: Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Source link

Previous NJ Governor's Race: Murphy's Pensions, Debt Record?
Next MPs and education experts suggest various models for schools to recoup learning losses

No Comment

Leave a reply

Your email address will not be published. Required fields are marked *